middle.news
Chimeric Seeks a Way Back as Creditors Hold the Key to Recapitalisation
10:16am on Thursday 1st of October, 2026 AEST
•
Biotechnology
Read Story
Chimeric Seeks a Way Back as Creditors Hold the Key to Recapitalisation
10:16am on Thursday 1st of October, 2026 AEST
Key Points
ASX suspension continues after FY2026 accounts miss the 30 September deadline
Approximate $7.7 million net asset deficiency and material going concern uncertainty
Creditor settlements, including with the convertible note holder, remain unresolved
Recapitalisation interest is conditional and no binding proposal has been received
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE